UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 293

Sortiert nach

Omitting surgery for early breast cancer showing clinical complete response to primary systemic therapy

Japanese journal of clinical oncology, 2020-05, Vol.50 (6), p.629-634

2020

Volltextzugriff (PDF)

Novel loci for hyperglycemia identified by QTL mapping of longitudinal phenotypes and congenic analysis

Scientific reports, 2023-01, Vol.13 (1), p.1315-1315, Article 1315

2023

Volltextzugriff (PDF)

Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)

International journal of clinical oncology, 2021-07, Vol.26 (7), p.1229-1236

2021

Volltextzugriff (PDF)

Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer

British journal of cancer, 2021-10, Vol.125 (9), p.1217-1225

2021

Volltextzugriff (PDF)

Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples

Scientific reports, 2019-09, Vol.9 (1), p.13343-8, Article 13343

2019

Volltextzugriff (PDF)

Multicenter Phase II Study of Intraoperative Radiotherapy of Early Breast Cancer: Ipsilateral Tumor Recurrence

Annals of surgical oncology, 2019-08, Vol.26 (8), p.2428-2434

2019

Volltextzugriff (PDF)

Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy

PloS one, 2022-11, Vol.17 (11), p.e0278344-e0278344

2022

Volltextzugriff (PDF)

Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy

PloS one, 2022-11, Vol.17 (11), p.e0278344

2022

Volltextzugriff (PDF)

Confirmation of Multiple Risk Loci and Genetic Impacts by a Genome-Wide Association Study of Type 2 Diabetes in the Japanese Population

Diabetes (New York, N.Y.), 2009-07, Vol.58 (7), p.1690-1699

2009

Volltextzugriff (PDF)

Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study

British journal of cancer, 2020-06, Vol.122 (12), p.1747-1753

2020

Volltextzugriff (PDF)

Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study

Japanese journal of clinical oncology, 2023-03, Vol.53 (3), p.203-211

2023

Volltextzugriff (PDF)

A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer

Breast cancer research and treatment, 2020-04, Vol.180 (3), p.715-724

2020

Volltextzugriff (PDF)

Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study

Japanese journal of clinical oncology, 2022-05, Vol.52 (6), p.545-553

2022

Volltextzugriff (PDF)

A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017

Japanese journal of clinical oncology, 2012-10, Vol.42 (10), p.970-973

2012

Volltextzugriff (PDF)

Prevention and Treatment of Obesity, Insulin Resistance, and Diabetes by Bile Acid–Binding Resin

Diabetes (New York, N.Y.), 2007-01, Vol.56 (1), p.239-247

2007

Volltextzugriff (PDF)

The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs

Breast cancer (Tokyo, Japan), 2020-09, Vol.27 (5), p.973-981

2020

Volltextzugriff (PDF)

Acute worsening of glycemic control in a patient with type 2 diabetes and non‐small cell lung cancer after administration of lorlatinib

Clinical case reports, 2022-01, Vol.10 (1), p.e05283-n/a

2022

Volltextzugriff (PDF)

Intensive vs. Standard Post-Operative Surveillance in High-Risk Breast Cancer Patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204

Japanese journal of clinical oncology, 2015-10, Vol.45 (10), p.983-986

2015

Volltextzugriff (PDF)

Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study

Breast cancer (Tokyo, Japan), 2021-01, Vol.28 (1), p.145-160

2021

Volltextzugriff (PDF)

Granulocyte and Monocyte Adsorption Apheresis for Generalized Pustular Psoriasis: Therapeutic Outcomes in Three Refractory Patients

Therapeutic apheresis and dialysis, 2015-08, Vol.19 (4), p.336-341

2015

Volltextzugriff (PDF)

Novel effect of ezetimibe to inhibit the development of non-alcoholic fatty liver disease in Fatty Liver Shionogi mouse

Hepatology research, 2014-01, Vol.44 (1), p.102-113

2014

Volltextzugriff (PDF)

Tumor-infiltrating CD45RO+ memory cells are associated with a favorable prognosis breast cancer

Breast cancer (Tokyo, Japan), 2016-07, Vol.23 (4), p.668-674

2016

Volltextzugriff (PDF)

Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06)

Cancer medicine (Malden, MA), 2023-09, Vol.12 (17), p.17718-17730

2023

Volltextzugriff (PDF)

The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition

Breast cancer (Tokyo, Japan), 2016-05, Vol.23 (3), p.329-342

2016

Volltextzugriff (PDF)

1 – 25 von 293

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(251)
Mit Volltextzugriff
(271)

Publikationsform

Sprache

Englisch
(273)
Japanisch
(73)

Erscheinungsjahr

n.n

Thema

Science & Technology
(174)
Life Sciences & Biomedicine
(160)
Humans
(129)
Female
(92)
Middle Aged
(74)
Male
(66)
Aged
(54)
Adult
(51)
Oncology
(50)
Breast Cancer
(45)
Endocrinology & Metabolism
(44)
Biological And Medical Sciences
(38)
Animals
(37)
Medical Sciences
(35)
Diabetes Mellitus, Type 1 - Genetics
(34)
Mice
(29)
Surgery
(27)
Medicine
(26)
Patients
(26)
Medicine & Public Health
(25)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Omitting surgery for early breast cancer showing clinical complete response to primary systemic therapy

Novel loci for hyperglycemia identified by QTL mapping of longitudinal phenotypes and congenic analysis

Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)

Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer

Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples

Multicenter Phase II Study of Intraoperative Radiotherapy of Early Breast Cancer: Ipsilateral Tumor Recurrence

Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy

Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy

Confirmation of Multiple Risk Loci and Genetic Impacts by a Genome-Wide Association Study of Type 2 Diabetes in the Japanese Population

Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study

Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study

A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer

Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study

A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017

Prevention and Treatment of Obesity, Insulin Resistance, and Diabetes by Bile Acid–Binding Resin

The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs

Acute worsening of glycemic control in a patient with type 2 diabetes and non‐small cell lung cancer after administration of lorlatinib

Intensive vs. Standard Post-Operative Surveillance in High-Risk Breast Cancer Patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204

Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study

Granulocyte and Monocyte Adsorption Apheresis for Generalized Pustular Psoriasis: Therapeutic Outcomes in Three Refractory Patients

Novel effect of ezetimibe to inhibit the development of non-alcoholic fatty liver disease in Fatty Liver Shionogi mouse

Tumor-infiltrating CD45RO+ memory cells are associated with a favorable prognosis breast cancer

Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)

Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06)

The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition

Suchergebnisse filtern